• Nektar Therapeutics recently initiated the first two global registrational Phase 3 trials, ZENITH AD‑1 and ZENITH AD‑2, evaluating rezpegaldesleukin in patients aged 12 and older with moderate‑to‑severe atopic dermatitis across North America, Europe and Asia‑Pacific.
• This marks a key step for rezpegaldesleukin, a first‑in‑class T‑reg focused biologic with FDA Fast Track status, aiming for differentiated immune‑modulating treatment options in atopic dermatitis and other autoimmune diseases.
• We’ll now examine how launching these large Phase 3 ZENITH AD trials for rezpegaldesleukin could reshape Nektar’s investment narrative and risk profile.

The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Nektar Therapeutics Investment Narrative Recap

To own Nektar today, you need to believe that rezpegaldesleukin can translate its Phase 2b data into successful, registrational Phase 3 outcomes and eventually an approved product, despite the company’s ongoing losses and reliance on external capital. The launch of the ZENITH AD Phase 3 trials sharpens the near term catalyst around clinical readouts, but it also amplifies the key risk that large, costly late stage studies may not replicate earlier efficacy or safety results.

The most relevant recent announcement here is Nektar’s completion of multiple follow on equity offerings in early 2026, raising roughly US$1.0 billion in gross proceeds. Those fundraises help support the sizable ZENITH AD program and extend the cash runway around rezpegaldesleukin, but they have already led to substantial dilution and highlight how dependent the story remains on capital markets until there is a clear path to commercial revenue.

Yet behind the excitement around Phase 3, investors should be aware that continued cash burn and dilution risk could still...

Nektar Therapeutics' narrative projects $54.9 million revenue and $10.7 million earnings by 2029. This requires fairly flat yearly revenue growth and an earnings increase of about $168.8 million from -$158.1 million today.

Uncover how Nektar Therapeutics' forecasts yield a $153.25 fair value, a 117% upside to its current price.

Exploring Other Perspectives

Before this Phase 3 news, the most optimistic analysts were assuming revenue of about US$136.0 million and earnings of US$26.8 million by 2029, so compared with the baseline focus on cash burn and dilution, that is a far more bullish view of what REZPEG and Nektar’s platform might deliver, and it shows just how much opinions can diverge as new trial results and financing moves come into focus.

Explore 3 other fair value estimates on Nektar Therapeutics - why the stock might be worth just $153.22!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Nektar Therapeutics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Nektar Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Nektar Therapeutics' overall financial health at a glance.

Looking For Alternative Opportunities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Find 55 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.